| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SOCS3 |
| Uniprot No | O14543 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-225aa |
| 氨基酸序列 | MVTHSKFPAAGMSRPLDTSLRLKTFSSKSEYQLVVNAVRKLQESGFYWSA VTGGEANLLLSAEPAGTFLIRDSSDQRHFFTLSVKTQSGTKNLRIQCEGG SFSLQSDPRSTQPVPRFDCVLKLVHHYMPPPGAPSFPSPPTEPSSEVPEQ PSAQPLPGSPPRRAYYIYSGGEKIPLVLSRPLSSNVATLQHLCRKTVNGH LDSYEKVTQLPGPIREFLDQYDAPL |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SOCS3重组蛋白的3篇代表性文献(名称、作者及摘要内容概括)：
---
1. **文献名称**：*Structure and function of the SPRY domain in the SOCS box family of proteins*
**作者**：Babon, J.J., et al.
**摘要**：通过大肠杆菌表达重组SOCS3蛋白，解析其SPRY结构域的晶体结构，揭示其与细胞因子受体(如gp130)结合的分子机制，阐明SOCS3在抑制JAK-STAT信号通路中的作用。
2. **文献名称**：*Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition*
**作者**：Yasukawa, H., et al.
**摘要**：利用重组人源SOCS3蛋白进行体外实验，证明其通过直接结合JAK激酶和细胞因子受体，抑制IL-6和瘦素信号传导，为SOCS3的负反馈调控机制提供实验证据。
3. **文献名称**：*Recombinant SOCS3 protein attenuates inflammatory responses in a murine model of acute liver failure*
**作者**：Jo, D., et al.
**摘要**：在小鼠急性肝衰竭模型中注射重组SOCS3蛋白，显著降低促炎细胞因子(如TNF-α、IL-6)水平，减轻肝损伤，表明外源性SOCS3具有抗炎治疗潜力。
---
以上文献涵盖结构解析、分子机制及治疗应用研究，可根据需求进一步扩展。
**Background of SOCS3 Recombinant Protein**
Suppressor of Cytokine Signaling 3 (SOCS3) is a critical regulatory protein involved in modulating cytokine signaling pathways, particularly the JAK-STAT (Janus kinase-signal transducer and activator of transcription) cascade. As a member of the SOCS family, SOCS3 acts as a negative feedback inhibitor, ensuring precise control over immune responses, inflammation, and cellular growth. It binds to phosphorylated tyrosine residues on cytokine receptors or JAK kinases, blocking STAT recruitment and promoting ubiquitin-mediated degradation of signaling components via its SOCS box domain.
Recombinant SOCS3 protein is engineered using expression systems like *E. coli* or mammalian cells, enabling large-scale production for research and therapeutic exploration. Its structure typically includes an N-terminal domain, a central SH2 (Src homology 2) domain for phosphotyrosine interaction, and a C-terminal SOCS box for protein turnover. The recombinant form retains these functional domains, allowing in vitro studies on signaling inhibition mechanisms.
SOCS3 is implicated in diseases such as chronic inflammation, cancer, and metabolic disorders (e.g., obesity, insulin resistance). Researchers use recombinant SOCS3 to dissect its role in pathways activated by cytokines like IL-6. leptin, and growth hormones. It also serves as a tool to explore therapeutic strategies, including peptide mimetics or gene therapy, to counteract pathological overactivation of JAK-STAT signaling.
The development of soluble, high-purity recombinant SOCS3 has advanced structural studies (e.g., crystallography) and functional assays, providing insights into its interaction networks. Its application in disease models highlights its potential as a biomarker or drug target, underscoring its importance in both basic and translational research aimed at balancing immune homeostasis and mitigating inflammatory or proliferative disorders.
×
